Previous 10 | Next 10 |
home / stock / bayry / bayry news
Bayer, following the Monsanto M&A, has become one of the largest agrochemical company in the world. I wouldn't touch the company at normal valuation currently, following the liability risks. At 5-7X earnings, this company starts looking appealing on an asset-wide basis, howeve...
The world's largest pharmaceuticals and chemicals conglomerate took another big step into the gene therapy arena on Monday. Bayer (OTC: BAYRY) has agreed to acquire Asklepios BioPharmaceutical, a privately held U.S. company more commonly known as AskBio. Bayer will pay $2 billio...
Bayer AG (BAYRY) has agreed to acquire U.S. biotech company Asklepios BioPharmaceutical to strengthen its commitment in the field of cell and gene therapy business across different therapeutic areas.The Company will own full rights to AskBio's gene therapy platform, including a broad intellec...
The Bayer stock is one of the very poor performers on the stock market. Anyone who wants to will find a real bargain in this situation, which offers excellent long-term potential. Nevertheless, the stock is, at least in my eyes, only a holding-position. In this article, you will f...
The California Supreme Court declines to hear an appeal by Bayer ([[BAYRY]] -1.1%) seeking to reverse a 2018 jury verdict that the company's Roundup herbicide caused a groundskeeper's cancer, leaving the company with few options to avoid paying a $20.4M judgment.Bayer had challenged the verdi...
Bayer ([[BAYRY]] -2.4%) shares sink to their lowest since 2011 after the company lost a ruling at France's top court in a case filed by a farmer who was exposed to a now-banned herbicide.The Cour de Cassation says the company is responsible for injuries the farmer suffered after breathing fum...
Foghorn Therapeutics has filed to raise $120 million in a U.S. IPO. The firm is developing treatments for ocular cancer and other cancers. FHTX is still at a preclinical stage of development, so the IPO may be more suited to long-term hold institutional investors. For furthe...
Bayer Aktiengesellschaft (OTC: BAYRY) and Biogen (NASDAQ: BIIB) are both massive and multinational healthcare companies, but the case in favor of investing in each company is dramatically different. Whereas Biogen's stock requires a steady drumbeat of new drug approvals and ...
Developing not only one but various models for a business leads to valuable additional insights. In this article, I provide an adjusted EPS projection, a sum-of-the-parts valuation and a cash flow model. The result is not surprising, but we gain a deeper understanding from the exe...
The earnings season came to a close and markets were mostly flat. I am continuing my monthly investment plans and suspiciously follow the massive rally in technology stocks. Whether it is a bubble or not, I won't stop investing. My dividend income from 37 corporations amounted...
News, Short Squeeze, Breakout and More Instantly...
Bayer AG ADR Company Name:
BAYRY Stock Symbol:
OTCMKTS Market:
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
Carisma Therapeutics Inc. (CARM) is expected to report $-0.56 for Q4 2023 First Acceptance Corp. (FACO) is expected to report for quarter end 2023-12-31 Bell Copper Corp (BCUFF) is expected to report for quarter end 2023-12-31 BioHarvest Sciences Inc (CNVCF) is expected to report for ...